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BACKGROUND
Cohort studies in Bangladesh showed promising cure rates among patients with 
multidrug-resistant tuberculosis who received existing drugs in regimens shorter 
than that recommended by the World Health Organization (WHO) in 2011.
METHODS
We conducted a phase 3 noninferiority trial in participants with rifampin-resistant 
tuberculosis that was susceptible to fluoroquinolones and aminoglycosides. Partici-
pants were randomly assigned, in a 2:1 ratio, to receive a short regimen (9 to 11 
months) that included high-dose moxifloxacin or a long regimen (20 months) that 
followed the 2011 WHO guidelines. The primary efficacy outcome was a favorable 
status at 132 weeks, defined by cultures negative for Mycobacterium tuberculosis at 
132 weeks and at a previous occasion, with no intervening positive culture or previous 
unfavorable outcome. An upper 95% confidence limit for the between-group dif-
ference in favorable status that was 10 percentage points or less was used to de-
termine noninferiority.
RESULTS
Of 424 participants who underwent randomization, 383 were included in the modified 
intention-to-treat population. Favorable status was reported in 79.8% of participants 
in the long-regimen group and in 78.8% of those in the short-regimen group — a 
difference, with adjustment for human immunodeficiency virus status, of 1.0 percent-
age point (95% confidence interval [CI], −7.5 to 9.5) (P = 0.02 for noninferiority). 
The results with respect to noninferiority were consistent among the 321 participants 
in the per-protocol population (adjusted difference, –0.7 percentage points; 95% CI, 
−10.5 to 9.1). An adverse event of grade 3 or higher occurred in 45.4% of participants 
in the long-regimen group and in 48.2% in the short-regimen group. Prolongation of 
either the QT interval or the corrected QT interval (calculated with Fridericia’s 
formula) to 500 msec occurred in 11.0% of participants in the short-regimen group, 
as compared with 6.4% in the long-regimen group (P = 0.14); because of the greater 
incidence in the short-regimen group, participants were closely monitored and some 
received medication adjustments. Death occurred in 8.5% of participants in the 
short-regimen group and in 6.4% in the long-regimen group, and acquired resistance 
to fluoroquinolones or aminoglycosides occurred in 3.3% and 2.3%, respectively.
CONCLUSIONS
In persons with rifampin-resistant tuberculosis that was susceptible to fluoroquinolones 
and aminoglycosides, a short regimen was noninferior to a long regimen with respect 
to the primary efficacy outcome and was similar to the long regimen in terms of 
safety. (Funded by the U.S. Agency for International Development and others; Current 
Controlled Trials number, ISRCTN78372190; ClinicalTrials.gov number, NCT02409290.)
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Multidrug-resistant tuberculosis is resistant to isoniazid and rifampin (also called rifampicin), key drugs used 
in the treatment of tuberculosis.1 The condition 
affects almost 500,000 new persons worldwide 
each year and is considerably more difficult to 
treat than drug-susceptible tuberculosis. Less than 
a quarter of patients start treatment, and the re-
ported success rates were 48% in 20122 and 54% 
in 2017.1 Despite the magnitude of the problem, 
data from phase 3 randomized trials of combina-
tion drug regimens for multidrug-resistant tuber-
culosis are lacking. Recommendations from the 
World Health Organization (WHO) for the treat-
ment of multidrug-resistant tuberculosis (pub-
lished in 2011) are based on evidence that was 
classified as very low quality and were described 
as conditional (i.e., “the desirable effects of adher-
ence to a recommendation probably outweigh the 
undesirable effects”).3 The 2011 WHO guidelines 
recommended an intensive treatment phase of 
8 months and a total treatment duration of 20 
months.3
In view of the lack of an effective standardized 
regimen that is appropriate for resource-poor set-
tings, Van Deun and colleagues conducted obser-
vational cohort studies in Bangladesh to evaluate 
several regimens for multidrug-resistant tubercu-
losis in patients who had not received previous 
treatment with second-line drugs. The sixth regi-
men, administered to 206 participants for 9 to 
11 months, yielded encouraging results, with re-
lapse-free cure occurring in 87.9% (95% confi-
dence interval [CI], 82.7 to 91.6).4 Although such 
a regimen could have considerable advantages over 
the much longer WHO-recommended regimen, 
we considered that a randomized trial would be 
necessary for reproducibility and generalizability 
of results, particularly because human immuno-
deficiency virus (HIV) coinfection and second-line 
drug resistance were rare among the participants 
in the Bangladesh study.
Me thods
Design and Oversight
We conducted a randomized, phase 3, noninferi-
ority trial (Standard Treatment Regimen of Anti-
Tuberculosis Drugs for Patients with MDR-TB 
[STREAM]5) to compare a short regimen (9 to 11 
months) for multidrug-resistant tuberculosis that 
was similar to the one used in a Bangladesh study4 
with a long regimen (20 months), used locally at 
each trial site, that followed the 2011 WHO guide-
lines.3 The trial methods have been published 
previously,5 and additional details are provided in 
the Supplementary Appendix and in the protocol 
and statistical analysis plan, all available with the 
full text of this article at NEJM.org. All the authors 
vouch for the accuracy and completeness of the 
data and for the fidelity of the trial to the protocol.
Participants
Participants were eligible for inclusion in the trial 
if they were 18 years of age or older and had pul-
monary tuberculosis (as confirmed by a positive 
sputum smear or, if coinfected with HIV, a nucle-
ic acid amplification test [GeneXpert, Cepheid]) 
with evidence of resistance to rifampin. In prac-
tice, the management of rifampin-monoresistant 
tuberculosis and the management of multidrug-
resistant tuberculosis are similar. Participants 
were ineligible if they were infected with a strain 
of Mycobacterium tuberculosis that was resistant to 
a second-line injectable drug or a fluoroquinolone 
(as determined by line-probe assay).6 Written in-
formed consent was obtained from all participants.
Treatment
The short regimen consisted of moxifloxacin (high-
dose), clofazimine, ethambutol, and pyrazinamide 
administered over a 40-week period, supplemented 
by kanamycin, isoniazid, and prothionamide in 
the first 16 weeks (dose information is provided 
in the Supplementary Appendix). The intensive 
phase could be extended to 20 or 24 weeks for 
participants who did not have conversion to a 
negative smear by 16 or 20 weeks, respectively. The 
regimen was identical to that used by Van Deun 
and colleagues in Bangladesh,4 except that moxi-
floxacin was substituted for gatifloxacin because 
quality-assured gatif loxacin was not available. 
Moxifloxacin was administered in doses deter-
mined according to body-weight category (400-mg 
dose for <33 kg, 600-mg dose for 33 to 50 kg; and 
800-mg dose for >50 kg). The medications in the 
long regimen were provided by the National Tu-
berculosis Programs in the respective countries. 
The medications in the short regimen were pur-
chased by the International Union against Tuber-
culosis and Lung Disease from quality-assured 
sources.
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Procedures
Participants and clinicians were aware of treat-
ment-group assignments, but the laboratory staff 
was not. Only the members of the independent 
data monitoring committee and the statisticians 
reviewed the aggregate data according to the 
treatment-group assignment during the trial. The 
participants had scheduled weekly visits during 
the first 4 weeks and thereafter were clinically 
evaluated at 4-week intervals through week 132; 
sputum samples for smear and culture were ob-
tained at every visit starting at the week 4 visit. 
M. tuberculosis isolates were sent to the trial refer-
ence laboratory for drug susceptibility testing and 
strain genotyping to distinguish relapses from 
reinfections. Regular electrocardiographic (ECG) 
monitoring was performed because of the risk of 
prolongation of the QT interval with high-dose 
moxifloxacin and clofazimine.7,8 Prolongations 
of the corrected QT interval, calculated with the 
use of Fridericia’s formula (QTcF), to 500 msec or 
greater were investigated, and treatment was mod-
ified if the prolongation was considered to be drug 
related by the site investigators. A full list of the 
assessments performed in the trial is provided 
in the Supplementary Appendix.5
Primary Outcomes
The primary efficacy outcome was a favorable sta-
tus at 132 weeks, which was defined by cultures 
that were negative for M. tuberculosis at 132 weeks 
after randomization and at a previous occasion 
during the trial period, with no intervening posi-
tive culture or previous unfavorable outcome. An 
unfavorable outcome was defined by the initia-
tion of two or more drug therapies that were not 
included in the assigned regimen, treatment ex-
tension beyond the permitted duration, death 
from any cause, a positive culture from one of 
the two most recent specimens, or no visit at 76 
weeks or later. Participants who had reinfections 
with a different strain and those whose last two 
cultures were negative (including one at 76 weeks) 
but were lost to follow-up thereafter were consid-
ered to be unable to be assessed and were ex-
cluded from the primary analysis.
The primary safety outcome was the occur-
rence of a (severe) adverse event of grade 3 or 
higher (as classified according to the Division of 
AIDS, National Institute of Allergy and Infec-
tious Diseases9) at any time during the treatment 
or follow-up period. Adverse events were coded 
with the use of the Medical Dictionary for Regulatory 
Activities (MedDRA), version 20.0. An independent 
death review committee, the members of which 
were unaware of the treatment-group assignments, 
classified the probable cause of death as being re-
lated to tuberculosis, tuberculosis treatment, HIV 
or HIV treatment, or other or uncertain.
Secondary Outcomes
Secondary efficacy outcomes were times to smear 
and culture conversions; acquired resistance to 
fluoroquinolones, aminoglycosides, and pyrazin-
amide; and a Bayesian interpretation of the re-
sults. Secondary safety outcomes were death dur-
ing the treatment and follow-up periods, an 
analysis of severe adverse events by MedDRA 
class, an analysis of QT interval prolongation, 
and changes in liver function test results.
Randomization and Trial Populations
Participants were assigned in a 2:1 ratio to the 
short regimen or the long regimen; randomiza-
tion was stratified according to trial site and HIV 
status. The modified intention-to-treat popula-
tion comprised all participants who underwent 
randomization and had a culture that was posi-
tive for M. tuberculosis at screening or randomiza-
tion, with the exception of those in whom isolates 
obtained before randomization were subsequently 
found to be susceptible to rifampin or resistant 
to both fluoroquinolones and second-line inject-
able drugs on phenotypic drug-susceptibility test-
ing. The per-protocol population comprised the 
participants in the modified intention-to-treat 
population, with the exception of those who did 
not complete a protocol-adherent course of treat-
ment for reasons other than treatment failure or 
death. All participants who received at least one 
dose of a trial medication were included in the 
safety analyses.
Statistical Analysis
Assuming that 75% of the participants in the 
short-regimen group and 70% in the long-regimen 
group would attain favorable status and assum-
ing that in a per-protocol analysis efficacy would 
not be able to be assessed in up to 20% of the 
participants, we estimated that 398 participants 
would need to be enrolled for the trial to have 
80% power to show the noninferiority of the short 
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424 Underwent randomization
689 Patients were assessed for eligibility
265 (38.5%) Were excluded
105 Did not have a positive smear or GeneXpert test
42 Had Mycobacterium tuberculosis that was sensitive to rifampin 
34 Had M. tuberculosis that was resistant to fluoroquinolone 
or a second-line injectable drug
20 Did not give informed consent
15 Were unlikely to survive >4 mo
13 Had a condition that made study participation unsafe 
in the opinion of an investigator
7 Had inconclusive results regarding resistance to rifampin
4 Had an AST or ALT level >5 times the ULN
4 Were unable to produce sputum
3 Had a fluorescein diacetate stain negative for M. tuberculosis 
18 Had other unspecified reason
142 Were assigned to the long-
regimen group
282 Were assigned to the short-
regimen group
6 (4.6%) Were not able to be
assessed in the modified
intention-to-treat efficacy
analysis
5 Had a negative culture at the
most recent visit but were
lost to follow-up after 76 wk
1 Had reinfection
8 (3.2%) Were not able to be
assessed in the modified
intention-to-treat efficacy
analysis
1 Had a negative culture at the
most recent visit but was
lost to follow-up after 76 wk
7 Had reinfection
4 (4.6%) Were not able to be
assessed in the per-protocol
efficacy analysis
3 Had a negative culture at the
most recent visit but were
lost to follow-up after 76 wk
1 Had reinfection
7 (3.0%) Were not able to be
assessed in the per-protocol
efficacy analysis
1 Had a negative culture at the
most recent visit but was
lost to follow-up after 76 wk
6 Had reinfection
130 (91.5%) Were included in the modified
intention-to-treat population
253 (89.7%) Were included in the modified
intention-to-treat population
245 (96.8%) Were included 
in the modified intention-to-
treat efficacy analysis 
124 (95.4%) Were included 
in the modified intention-to-
treat efficacy analysis 
87 of 142 (61.3%) Were included in the
per-protocol population
83 (95.4%) Were included in the
per-protocol efficacy analysis
227 (97.0%) Were included in the
per-protocol efficacy analysis
234 of 282 (83.0%) Were included in the
per-protocol population
12 (8.5%) Were excluded
7 Did not have positive
culture at baseline
2 Had rifampin sensitivity
detected at the trial
reference laboratory
2 Underwent randomization
in error
1 Had extensively drug-
resistant tuberculosis
detected at the trial
reference laboratory
29 (10.3%) Were excluded
18 Did not have positive
culture at baseline
6 Had rifampin sensitivity
detected at the trial
reference laboratory
4 Underwent randomization
in error
1 Had extensively drug-
resistant tuberculosis
detected at the trial
reference laboratory
43 of 142 (30.3%) Were not
eligible for inclusion in the
per-protocol population
because they did not complete
an adequate course of treatment
19 of 282 (6.7%) Were not
eligible for inclusion in the
per-protocol population
because they did not complete
an adequate course of treatment
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regimen to the long regimen, at one-sided level of 
significance of 0.025. Additional details are pro-
vided in the Supplementary Appendix. In the pri-
mary efficacy analysis, we calculated the absolute 
between-group difference (with the 95% confi-
dence interval) in the percentage of participants 
who attained favorable status, with adjustment 
for HIV status using Cochran–Mantel–Haenszel 
weights.10 Noninferiority would be shown if the 
upper boundary of the 95% confidence interval 
was 10 percentage points or less in both the 
modified intention-to-treat and per-protocol pop-
ulations. A 10 percentage-point noninferiority 
margin was considered to be an acceptable dif-
ference in efficacy, given the shorter treatment 
duration.
One-sided tests for noninferiority and calcu-
lations of the 95% confidence intervals were per-
formed with the use of the Wald standard error. 
We also conducted a post hoc secondary Bayes-
ian analysis of noninferiority.11
R esult s
Participants
From July 2012 through June 2015, a total of 689 
participants were screened, of whom 424 under-
went randomization; 282 participants were as-
signed to the short-regimen group and 142 to the 
long-regimen group. A total of 126 participants 
resided in Ethiopia, 33 in Mongolia, 165 in South 
Africa, and 100 in Vietnam. The modified inten-
tion-to-treat population comprised 383 partici-
pants, of whom 369 were included in the modified 
intention-to-treat efficacy analysis, and the per-
protocol population comprised 321 participants, 
of whom 310 were included in the per-protocol 
efficacy analysis. Reasons for exclusion are shown 
in Figure 1.
The demographic characteristics of participants 
at baseline did not differ significantly between the 
treatment groups (Table 1, and Table S2 in the 
Supplementary Appendix). In the modified inten-
tion-to-treat population, 32.6% of the participants 
were infected with HIV and 77.2% had cavitation. 
The median duration of treatment among those 
who completed the assigned regimen was 40.1 
weeks (5th and 95th percentiles, 37.0 and 46.3) 
in the short-regimen group and 82.7 weeks (5th 
and 95th percentiles, 72.1 and 102.3) in the long-
regimen group. In the short-regimen group, the 
intensive phase of treatment was extended by 
4 weeks in 10 participants (4.0%) and by 8 weeks 
in 3 participants (1.2%) because of a delayed con-
version to a negative smear.
At 132 weeks, 94.1% of the participants in the 
short-regimen group and 90.0% in the long-regi-
men group in the modified intention-to-treat 
population were either assessed or were known 
to have died, and 1.2% and 5.4%, respectively, 
were lost to follow-up (Table S3 in the Supple-
mentary Appendix). In the modified intention-
to-treat population, 75.1% of the participants in 
the short-regimen group and 43.1% in the long-
regimen group were fully adherent to the assigned 
regimen (Fig. S1 in the Supplementary Appendix).
Primary Efficacy Outcome
In the modified intention-to-treat efficacy analysis, 
favorable status was reported in 99 of 124 par-
Figure 1 (facing page). Screening, Randomization,  
and Analysis of the Trial Populations.
The modified intention-to-treat population comprised 
all participants who underwent randomization and 
had a positive culture for Mycobacterium tuberculosis 
at screening or randomization, with the exception of 
those in whom isolates obtained before randomiza-
tion were subsequently found to be susceptible to ri-
fampin or resistant to both fluoroquinolones and second-
line injectable drugs on phenotypic drug susceptibility 
testing. The per-protocol population comprised the 
participants in the modified intention-to-treat popula-
tion, with the exception of those who did not complete 
a protocol-adherent course of treatment for reasons 
other than treatment failure or death. The short regi-
men (9 to 11 months) consisted of moxifloxacin (high-
dose), clofazimine, ethambutol, and pyrazinamide ad-
ministered over a 40-week period, supplemented by 
kanamycin, isoniazid, and prothionamide in the first 
16 weeks; the intensive phase could be extended to  
20 or 24 weeks for participants who did not have a 
conversion to a negative smear by 16 or 20 weeks, re-
spectively. The long regimen (20 months) followed the 
2011 World Health Organization guidelines. Four par-
ticipants assigned to the short-regimen group under-
went randomization in error and were immediately 
withdrawn from the trial — one had a rapid test posi-
tive for fluoroquinolone-resistant tuberculosis, one 
was underage, one had a positive pregnancy test, and 
one had a GeneXpert (Cepheid) result that was misin-
terpreted. Two participants assigned to the long-regi-
men group underwent randomization in error and 
were immediately withdrawn from the study — one 
had a rapid test positive for aminoglycoside-resistant 
tuberculosis, and one had rifampin sensitivity detect-
ed on a GeneXpert test. ALT denotes alanine amino-
transferase, AST aspartate aminotransferase, and 
ULN upper limit of the normal range.
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ticipants (79.8%) in the long-regimen group and 
in 193 of 245 participants (78.8%) in the short-
regimen group — a difference, with adjustment 
for HIV status, of 1.0 percentage point (95% CI, 
−7.5 to 9.5) (P = 0.02 for noninferiority). The time 
to an unfavorable outcome did not differ signifi-
cantly between the treatment groups (Fig. 2A). In 
the per-protocol efficacy analysis, favorable status 
Characteristic
Long Regimen 
(N = 130)
Short Regimen 
(N = 253)
Total 
(N = 383)
Male sex — no./total no. (%) 83/130 (63.8) 151/253 (59.7) 234/383 (61.1)
Age — no./total no. (%)
<25 yr 31/130 (23.8) 56/253 (22.1) 87/383 (22.7)
25–34 yr 45/130 (34.6) 88/253 (34.8) 133/383 (34.7)
35–44 yr 33/130 (25.4) 58/253 (22.9) 91/383 (23.8)
≥45 yr 21/130 (16.2) 51/253 (20.2) 72/383 (18.8)
Weight — no./total no. (%)
<33 kg 0 1/253 (0.4) 1/383 (0.3)
33–50 kg 59/130 (45.4) 116/253 (45.8) 175/383 (45.7)
>50 kg 71/130 (54.6) 136/253 (53.8) 207/383 (54.0)
Positive HIV status — no./total no. (%) 40/130 (30.8) 85/253 (33.6) 125/383 (32.6)
Median CD4 cell count in HIV-infected par-
ticipants (IQR)†
298 (166–532) 239 (139–394) 248 (143–429)
Radiographic extent of disease — no./total 
no. (%)‡
None or minimal 14/125 (11.2) 28/239 (11.7) 42/364 (11.5)
Moderate 72/125 (57.6) 126/239 (52.7) 198/364 (54.4)
Advanced 39/125(31.2) 85/239 (35.6) 124/364 (34.1)
Radiographic extent of cavitation — no./to-
tal no. (%)‡
None 28/125 (22.4) 55/239 (23.0) 83/364 (22.8)
Single 13/125 (10.4) 34/239 (14.2) 47/364 (12.9)
Multiple 84/125 (67.2) 150/239 (62.8) 234/364 (64.3)
QTcF interval — no./total no. (%)
<400 msec 58/130 (44.6) 112/253 (44.3) 170/383 (44.4)
400–449 msec 71/130 (54.6) 136/253 (53.8) 207/383 (54.0)
450–499 msec 1/130 (0.8) 5/253 (2.0) 6/383 (1.6)
*  The modified intention-to-treat population comprised all participants who underwent randomization and had a culture 
positive for Mycobacterium tuberculosis at screening or randomization, with the exception of those in whom isolates ob-
tained before randomization were subsequently found to be susceptible to rifampin or resistant to both fluoroquino-
lones and second-line injectable drugs on phenotypic drug susceptibility testing. The short regimen (9 to 11 months) 
consisted of moxifloxacin (high-dose), clofazimine, ethambutol, and pyrazinamide administered over a 40-week period, 
supplemented by kanamycin, isoniazid, and prothionamide in the first 16 weeks; the intensive phase could be extended 
to 20 or 24 weeks for participants who did not have a conversion to a negative smear by 16 or 20 weeks, respectively. 
The long regimen (20 months) followed the 2011 World Health Organization guidelines. There were no significant be-
tween-group differences in the characteristics at baseline. A complete list of the baseline characteristics is provided in 
Table S2 in the Supplementary Appendix. HIV denotes human immunodeficiency virus, IQR interquartile range, and 
QTcF corrected QT interval, calculated with Fridericia’s formula.
†  CD4 cell counts were missing for 52 HIV-infected participants (13 in the long-regimen group and 39 in the short-regi-
men group).
‡  The results of chest radiography could not be assessed in 19 participants (5 in the long-regimen group and 14 in the 
short-regimen group).
Table 1. Baseline Characteristics of the Participants in the Modified Intention-to-treat Population.*
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Figure 2. Kaplan–Meier Estimates of the Time to an Unfavorable Outcome and the Time to Death.
Panel A shows the Kaplan–Meier estimates of the time to an unfavorable outcome, which was defined by the initia-
tion of two or more drug therapies that were not included in the assigned regimen, treatment extension beyond the 
permitted duration, death from any cause, a positive culture for Mycobacterium tuberculosis from one of the two 
most recent specimens, or no visit at 76 weeks or later. In contrast, favorable status at 132 weeks (the primary out-
come) was defined by cultures that were negative for M. tuberculosis at 132 weeks after randomization and at a pre-
vious occasion during the trial period, with no intervening positive culture or previous unfavorable outcome. Panel 
B shows the Kaplan–Meier estimates of the time to death. In both panels, insets show the same data on an en-
larged y axis.
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Variable Modified Intention-to-Treat Population Per-Protocol Population
Long 
Regimen
Short 
Regimen Total
Long 
Regimen
Short 
Regimen Total
Disposition of the participants
Underwent randomization — no. 142 282 424 142 282 424
Were included in the population — no. 130 253 383 87 234 321
Were considered not able to be assessed — no.
Had reinfection with a different strain 1 7 8 1 6 7
Had a negative culture at 76 weeks but lost to follow-up thereafter 5 1 6 3 1 4
Were included in primary outcome analysis — no. 124 245 369 83 227 310
Outcome
Attained favorable status — no. (%)† 99 (79.8) 193 (78.8) 292 (79.1) 67 (80.7) 186 (81.9) 253 (81.6)
Had an unfavorable outcome — no. (%) 25 (20.2) 52 (21.2) 77 (20.9) 16 (19.3) 41 (18.1) 57 (18.4)
Determined on the basis of bacteriologic findings‡
Had no negative cultures§ 1 5 6 1 5 6
Had bacteriologic reversion during treatment period¶ 4 13 17 4 11 15
Had bacteriologic relapse after treatment period and 
started ≥2 additional drug therapies‖
0 7 7 0 7 7
Had positive culture at last assessment** 2 1 3 2 1 3
Determined on the basis of criteria other than bacteriologic 
findings
Had negative culture at last assessment but died during 
the treatment or follow-up period
5 9 14 5 9 14
Had treatment extended or changed after adverse event 3 4 7 2 3 5
Started ≥2 additional drug therapies owing to decision by 
the investigator††
3 2 5 2 0 2
Withdrew consent for treatment, was given a different 
regimen, or was lost to follow-up before 76 weeks
4 8 12 0 3 3
Had treatment extended or changed after poor adher-
ence or loss to follow-up
0 2 2 0 1 1
Had negative culture at last assessment but was lost to 
follow-up before 76 weeks
3 1 4 0 1 1
*  The per-protocol population comprised the participants in the modified intention-to-treat population, with the exception of those who did 
not complete a protocol-adherent course of treatment for reasons other than treatment failure or death. When a participant had more 
than one event leading to an unfavorable outcome (e.g., relapse and then death), the outcome classification was based on the first event. 
Additional information is provided in Table S4 in the Supplementary Appendix.
†  The primary efficacy outcome was favorable status, defined by negative results on a culture for M. tuberculosis at 132 weeks after random-
ization and at a previous occasion during the trial period, with no intervening positive culture or previous unfavorable outcome. The unad-
justed between-group difference in the percentage of participants who attained favorable status (long-regimen group minus short-regimen 
group) was 1.1 percentage points (95% confidence interval [CI], −7.7 to 9.8) in the modified intention-to-treat analysis (P = 0.02 for nonin-
feriority) and −1.2 percentage points (95% CI, −11.1 to 8.6) in the per-protocol analysis (P = 0.01 for noninferiority). After adjustment for 
human immunodeficiency virus status, the corresponding between-group differences were 1.0 percentage point (95% CI, −7.5 to 9.5) and 
−0.7 percentage points (95% CI, −10.5 to 9.1) (P = 0.02 for noninferiority in both analyses).
‡  Participants were considered to have bacteriologic reversion or relapse if they started at least two new additional drug therapies after the 
recurrence of positive cultures either during the treatment period (reversion) or after the treatment period (relapse).
§  All the participants who had no negative cultures throughout the trial died, except for one participant in the short-regimen group who had 
started at least two additional drug therapies.
¶  All the participants who had bacteriologic reversion during treatment period started at least two additional drug therapies, except for one participant in 
the short-regimen group for whom treatment was extended beyond what was permitted, one participant in each regimen group who died, and one 
participant in the short-regimen group who was lost to follow-up before 76 weeks. One reversion that occurred in the long-regimen group was deter-
mined on the basis of limited bacteriologic findings (i.e., only an isolated positive culture that was associated with clinical signs and symptoms).
‖  One relapse that occurred in the short-regimen group was determined on the basis of limited bacteriologic findings (i.e., an isolated posi-
tive culture that was associated with clinical signs and symptoms).
**  One participant in the short-regimen group had a positive culture when last assessed before death, and two participants in the long-regi-
men group had a positive culture when last assessed at the end of follow-up (week 132).
††  The investigator’s decision to start two or more additional drug therapies was based on the following reasons: results of baseline drug 
susceptibility testing (three participants in the long-regimen group), pregnancy (one participant in the short-regimen group), and switch 
to the same regimen as received by a participant’s child (one participant in the short-regimen group).
Table 2. Primary Efficacy Analysis in the Modified Intention-to-Treat and Per-Protocol Populations.*
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was reported in 67 of 83 participants (80.7%) in 
the long-regimen group and in 186 of 227 par-
ticipants (81.9%) in the short-regimen group — 
an adjusted difference of −0.7 percentage points 
(95% CI, −10.5 to 9.1) (P = 0.02 for noninferiority). 
Among the participants included in the modified 
intention-to-treat efficacy analysis, unfavorable 
bacteriologic outcomes were more common in 
the short-regimen group than in the long-regimen 
group (26 participants [10.6%] vs. 7 participants 
[5.6%]); an unfavorable outcome due to loss to 
follow-up was more common in the long-regimen 
group than in the short-regimen group (3 partici-
pants [2.4%] vs. 1 participant [0.4%]) (Table 2). 
The treatment effect did not differ significantly 
between the treatment groups in any subgroup 
evaluated in the modified intention-to-treat anal-
ysis population, including the subgroup defined 
according to HIV status (Fig. S2 in the Supple-
mentary Appendix).
Secondary Outcomes
The median times to conversion to a negative 
smear and culture did not differ significantly 
between the treatment groups. Resistance to fluo-
roquinolones or aminoglycosides developed in 
8 participants (3.3%) in the short-regimen group 
and in 3 (2.3%) in the long-regimen group (P = 0.62). 
Resistance to pyrazinamide developed in no par-
ticipants. Using a flat uninformative prior distri-
bution, we calculated that the Bayesian probabil-
ity that the between-group difference in the 
percentage of participants who would attain fa-
vorable status would be less than 10 percentage 
points was 0.98 and the probability that it would 
be less than 5 percentage points was 0.83. The 
Bayesian mean estimate of the risk difference 
was 0.8 percentage points (95% credible interval, 
−8.1 to 9.3). (Additional details on the secondary 
outcome analyses are provided in Figs. S4 through 
S7 and Fig. S11 and Table S6 in the Supplemen-
tary Appendix.)
Safety
In the safety population, a severe adverse event 
occurred in 136 of 282 participants (48.2%) in 
the short-regimen group, as compared with 64 
of 141 participants (45.4%) in the long-regimen 
group. A total of 33 participants died during the 
treatment or follow-up period — 24 (8.5%) in 
the short-regimen group and 9 (6.4%) in the 
long-regimen group (hazard ratio, 1.38; 95% CI, 
0.64 to 2.96) (Table 3 and Fig. 2B); most of the 
difference between the treatment groups occurred 
during the first year, after which the rates became 
similar. Four cases of sudden death at home oc-
curred during the treatment period — two deaths 
(one in the short-regimen group and one in the 
long-regimen group) were attributed by the death 
review committee to tuberculosis treatment, and 
the remaining two deaths (both in the short-
regimen group) were attributed to other causes 
(Table S7 in the Supplementary Appendix). In 
the two of the three sudden deaths that occurred 
in the short-regimen group, a QT or QTcF inter-
val of 500 msec or more had been recorded; one 
of these deaths was attributed to treatment and 
the other to other causes. Among the partici-
pants who had HIV coinfection at baseline, 18 of 
103 (17.5%) in the short-regimen group died, as 
compared with 4 of 50 (8.0%) in the long-regi-
men group (hazard ratio in a post hoc analysis, 
2.23; 95% CI, 0.76 to 6.60).
Five of the MedDRA system organ classes ac-
counted for the majority of severe adverse events 
(Table S8 in the Supplementary Appendix). More 
participants in the short-regimen group than in 
the long-regimen group had cardiac disorders, 
particularly those classified as conduction disor-
ders (9.9% vs. 5.0%), whereas more participants 
in the long-regimen group than in the short-reg-
imen group had metabolic disorders, particularly 
those classified as hypokalemia (7.1% vs. 1.1%). 
Hepatobiliary disorders were slightly more com-
mon in the short-regimen group than in the long-
regimen group (8.9% vs. 5.7%), but the percent-
age of patients with either ear and labyrinth or 
respiratory disorders did not differ notably.
The ECG monitoring showed that prolonga-
tion of the QT or QTcF interval to 500 msec or 
more developed in more participants in the short-
regimen group than in the long-regimen group 
(11.0% vs. 6.4%, P = 0.14); such prolongations 
occurred throughout the treatment period (Fig. S8 
in the Supplementary Appendix). There was little 
difference with respect to prolongation of the 
QT or QTcF interval between the two high doses 
of moxifloxacin that were used in the trial (Table 
S10 in the Supplementary Appendix). The treat-
ment was modified in response to prolongation 
of the QT or QTcF interval in 33 participants (32 
[11.3%] in the short-regimen group); the moxi-
floxacin dose was reduced in 21 participants, and 
moxifloxacin was switched to levofloxacin in 12 
participants, of whom 3 also discontinued clofazi-
mine and 1 continued clofazimine at half the dose.
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An alanine aminotransferase level exceeding 
five times the upper limit of the normal range 
was reported in 18 of 272 participants (6.6%) in 
the short-regimen group, as compared with 2 of 
139 participants (1.4%) in the long-regimen group 
(P = 0.03); in a time-to-event analysis, the hazard 
ratio for a measurement exceeding five times the 
upper limit of the normal range after randomiza-
tion in the short-regimen group as compared with 
the long-regimen group was 5.64 (95% CI, 1.30 
to 24.38) (Table S11 and Fig. S9 in the Supplemen-
tary Appendix). Aspartate aminotransferase levels 
did not differ significantly between the treatment 
groups.
Discussion
We found that the efficacy of the short regimen 
(9 to 11 months) that had been studied previously 
in Bangladesh (modified in the current trial to in-
clude high-dose moxifloxacin in place of high-
dose gatifloxacin) was noninferior to the long 
regimen (20 months) that followed the 2011 WHO 
recommendations. Both regimens resulted in a 
long-term successful outcome in more than 78% 
of the participants, with more participants in the 
short-regimen group having an unfavorable out-
come (HIV-adjusted difference, 1.0 percentage 
point), although this difference could have been 
7.5 percentage points in favor of the short regi-
men or 9.5 percentage points in favor of the long 
regimen. The Bayesian analysis yielded a proba-
bility of 0.83 that this difference would be no more 
than 5 percentage points. Our final estimate of the 
difference in efficacy between the two regimens, 
based on data from 369 participants in the mod-
ified intention-to-treat analysis, did not differ 
notably from the preliminary findings that were 
based on data from 318 participants (adjusted dif-
ference, 2.1 percentage points; 95% CI, −6.9 to 
11.2) that we reported at the Union World Con-
ference on Lung Health in October 2017.12
Outcome
Long Regimen 
(N = 141)
Short Regimen 
(N = 282)
Total 
(N = 423)
Grade 3 to 5 adverse event — no. (%) 64 (45.4) 136 (48.2) 200 (47.3)
Serious adverse event — no. (%) 53 (37.6) 91 (32.3) 144 (34.0)
Death — no. (%) 9 (6.4) 24 (8.5) 33 (7.8)
Related to tuberculosis 2 7 9
Related to tuberculosis treatment 1 1 2
Related to HIV or HIV treatment 3 6 9
Other or uncertain 3 10 13
Grade 3 to 5 adverse events according to 
the five most common MedDRA 
system organ classes — no. (%)
Metabolism and nutrition disorders 28 (19.9) 41 (14.5) 69 (16.3)
Hypokalemia† 10 (7.1) 3 (1.1) 13 (3.1)
Cardiac disorders 10 (7.1) 30 (10.6) 40 (9.5)
Conduction disorder† 7 (5.0) 28 (9.9) 35 (8.3)
Hepatobiliary disorders 8 (5.7) 25 (8.9) 33 (7.8)
Ear and labyrinth disorders 8 (5.7) 21 (7.4) 29 (6.9)
Respiratory, thoracic, and mediastinal 
disorders
6 (4.3) 15 (5.3) 21 (5.0)
*  All participants who received at least one dose of a trial medication were included in the safety analysis population. The 
primary safety outcome in the trial was a grade 3 to 5 adverse event at any point during the treatment and follow-up pe-
riods. Adverse events were coded with the use of Medical Dictionary for Regulatory Activities (MedDRA), version 20.0. An 
independent death review committee, the members of which were unaware of the treatment-group assignments, classi-
fied the probable cause of death as being related to tuberculosis, tuberculosis treatment, HIV or HIV treatment, or oth-
er or uncertain.
†  Hypokalemia and conduction disorder are preferred terms in MedDRA, version 20.0.
Table 3. Summary of Safety Outcomes.*
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The percentage of participants who had severe 
adverse events did not differ notably between the 
treatment groups. ECG monitoring was per-
formed in all the participants in the trial; this was 
shown to be necessary to identify and manage 
QT or QTcF interval prolongation that occurred 
in some participants in the short-regimen group 
throughout the treatment period. Unfavorable bac-
teriologic outcomes were more common among 
the participants in the short-regimen group and 
consisted mainly of bacteriologic reversion (dur-
ing the treatment period) and relapses (after the 
treatment period). This finding may be due in 
part to the fact that few participants in the short-
regimen group had an extension of the intensive 
phase because of slow conversion to a negative 
smear; in contrast, in the Bangladesh study, 
half the patients received treatment for more 
than 9 months.13 Although the follow-up time 
from randomization was the same in the two 
treatment groups, the difference in treatment 
duration allowed less time for post-treatment 
relapses to be identified among the participants 
in the long-regimen group. In the modified in-
tention-to-treat analysis, the short regimen was 
not shown to be inferior or superior to the long 
regimen in any subgroup evaluated.
Some acquired fluoroquinolone resistance was 
observed, but the percentage of participants in 
whom this developed did not differ significantly 
between the treatment groups. This finding is in 
contrast to the Bangladesh study, in which no 
such acquired resistance was observed in more 
than 500 patients13 and may be a consequence of 
the use of moxifloxacin in place of gatifloxacin, 
poorer adherence, or differences in clinical man-
agement.
The trial showed no evidence that the short 
regimen was associated with fewer severe adverse 
events over the 132 weeks of treatment and fol-
low-up. The type of event differed between the 
groups, particularly in relation to cardiac con-
duction disorders and hepatobiliary disorders, 
both of which were more common in the short 
regimen group, and metabolic disorders, which 
were more common in the long regimen group. 
Hearing loss with second-line injectable drugs is 
an important cause of disability. No evidence of 
a between-group difference in ear and labyrinth 
disorders was found, although these events may 
have been underestimated because trial sites out-
side South Africa did not have access to formal 
audiometry. There was limited evidence of a dif-
ference in mortality, with more deaths reported 
in the short-regimen group than in the long-reg-
imen group in the first year after starting treat-
ment. This difference was more pronounced 
among participants coinfected with HIV.
Regular ECG monitoring in all participants led 
to the recognition that the percentage of partici-
pants with severe conduction disorders (defined 
by a prolongation of the QT or QTcF interval to 
500 msec or more) was twice as high in the short-
regimen group as in the long-regimen group. 
Similarly, regular liver function testing during the 
intensive phase showed that the percentage of 
participants with grade 3 alanine aminotransfer-
ase elevations was higher in the short-regimen 
group than in the long-regimen group, which 
may have contributed to the excess of hepatobili-
ary disorders in the short-regimen group.
It was not possible to conduct the trial in a 
double-blind manner, and thus clinical decisions 
about when to change treatment may have been 
influenced by knowledge of the treatment-group 
assignment rather than have been based solely 
on the clinical condition of the participants. The 
open-label design may have influenced reporting 
of adverse events; however, trial sites were asked 
to report all grade 3 to 5 adverse events irrespec-
tive of whether they might be considered to be 
drug reactions. The current trial provides no evi-
dence regarding which of the seven drugs in the 
short regimen are essential. Other studies may 
assist in answering this question.14-17 The between-
country variation in the constitution of the long 
regimen might be considered a limitation, but 
there is no evidence of differential treatment ef-
fects between countries. Although the results of 
the per-protocol analysis were consistent with 
those of the modified intention-to-treat analysis 
with respect to the noninferiority of the short 
regimen to the long regimen, the larger percent-
age of participants in the long-regimen group than 
in the short-regimen group who were excluded 
from the per-protocol analysis (30.3% vs. 6.7%) 
limits the clinical usefulness of the findings.
These results are applicable only to patients 
infected with bacilli for which there was no ge-
notypic evidence of resistance to fluoroquino-
lones or injectable drugs. A second stage of the 
STREAM study (Current Controlled Trials num-
ber, ISRCTN18148631; and ClinicalTrials.gov num-
ber, NCT02409290) is currently evaluating wheth-
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er a fully oral short regimen would be effective 
and thereby avoid the toxic effects associated 
with aminoglycosides.14
Regular ECG monitoring to identify QT inter-
val prolongation and allow treatment modifica-
tion if required was shown to be useful through-
out the treatment period in the short-regimen 
group18; QT-related treatment modifications, most 
commonly a reduction in moxifloxacin dose, were 
made in 11.3% of participants assigned to the 
short-regimen group. There was little difference 
between the two moxifloxacin doses with re-
spect to QT interval prolongation. Our findings 
suggest that implementation of the short regi-
men with high-dose moxifloxacin would require 
regular ECG monitoring throughout the treat-
ment period. This would present a considerable 
challenge for clinical services, and in view of 
these findings, the fluoroquinolone used in the 
modified Bangladesh regimen in the second-
stage STREAM study has been changed to levo-
floxacin to evaluate whether this change would 
allow ECG monitoring to be reduced.
Our results were consistent with those of the 
Bangladesh study that involved more than 500 
participants,13 as well as those from smaller stud-
ies in Cameroon, Niger, Uzbekistan, and Swazi-
land.19-21 Key strengths of the trial were its ran-
domized design, the inclusion of participants 
coinfected with HIV, the diverse population (sites 
in four countries with different ethnic composi-
tions and health care systems), and a greater than 
90% rate of retention.
After reviewing the results of the STREAM 
study and of observational studies, the WHO re-
leased updated guidelines for multidrug-resistant 
and rifampin-resistant tuberculosis in December 
2018 that continued to include the short regimen 
as an option for patients “who have not been 
previously treated for more than one month with 
second-line medicines used in the shorter MDR 
[multidrug-resistant] regimen or in whom resis-
tance to fluoroquinolones and second-line in-
jectable agents has been excluded.”22 Although 
the results of this trial are encouraging, further 
research remains essential to find a short, sim-
ple regimen for multidrug-resistant tuberculosis 
that results in efficacy and safety outcomes that 
are similar to those for drug-susceptible tuber-
culosis.
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